Thymogen (EW dipeptide) is a Khavinson bioregulator consisting of glutamic acid and tryptophan, originally isolated from calf thymus extracts (Thymalin) in the late 1980s. Developed by Professor Vladimir Khavinson, it has been registered in Russia since 1990 in multiple forms including injectable solution, nasal spray, and topical cream. Thymogen modulates both humoral and cellular immunity, activates T-cell differentiation, and has demonstrated geroprotective (anti-aging) and antitumor activities in research studies.

Mechanism of Action

Thymogen works through multiple immunomodulatory mechanisms: (1) activates T-cell differentiation and T-cell recognition of peptide-MHC complexes, (2) induces changes in intracellular cyclic nucleotide composition, (3) activates neutrophilic chemotaxis and phagocytosis, (4) normalizes T-lymphocyte concentrations and ratios (CD3+, CD4+, CD8+), (5) stimulates production of immunoglobulins (IgA, IgG, IgE, IgM), and (6) enhances lymphocyte differentiation receptor expression. Research suggests Thymogen may interact specifically with the AACG DNA sequence, affecting gene expression. The peptide is rapidly distributed to thymus, lymph nodes, liver, adrenals, and kidneys.

Reconstitution Calculator

Safety Profile

Safety Profile: Thymogen

Common Side Effects

• Generally well tolerated in clinical studies, primarily conducted in Russia and Eastern European countries
• Mild nasal irritation or rhinitis when administered intranasally (the most common route)
• Mild injection site reactions (pain, redness) with parenteral administration
• Occasional headache and mild fatigue
• Mild allergic skin reactions including transient rash or pruritus

Serious Adverse Effects

• Limited Western clinical trial data; safety profile primarily based on Russian pharmacological literature
• Rare allergic reactions including urticaria and angioedema
• Theoretical risk of immune overstimulation in patients with autoimmune conditions, though clinical evidence is sparse
• No significant hepatotoxicity, nephrotoxicity, or hematological toxicity reported in available literature
• Long-term safety data beyond 10-day treatment courses are limited

Contraindications

• Known hypersensitivity to thymogen (L-glutamyl-L-tryptophan) or any formulation excipients
• Active autoimmune diseases (may exacerbate immune dysregulation)
• Pregnancy and lactation (insufficient safety data)
• Severe allergic conditions without medical supervision
• Concurrent use with other immunostimulants without medical oversight

Drug Interactions

• Immunosuppressants (cyclosporine, tacrolimus, methotrexate): May counteract immunosuppressive therapy due to immune-stimulating properties
• Other thymic peptides (thymalin, thymulin): Additive immunostimulatory effects; avoid concurrent use without medical supervision
• Corticosteroids: May partially antagonize the immunostimulatory effects of thymogen
• Vaccines: Theoretical enhancement of immune response to vaccines; timing should be discussed with a physician
• No significant CYP450 interactions reported

Population-Specific Considerations

• Elderly: Primary use population for immunosenescence; generally well tolerated at standard doses
• Pediatric: Used in Russian clinical practice for recurrent infections in children; dosing adjusted by age
• Immunocompromised patients: Primary indication, but requires medical supervision to calibrate immune response
• Post-surgical patients: Used in some protocols to reduce post-operative infection risk; ensure no conflict with other immunoactive medications
• Autoimmune patients: Generally contraindicated; immune stimulation may worsen disease activity

Pharmacokinetic Profile